- Home
- CRDF vs PAAI Comparison
CRDF vs PAAI Comparison
Compare CRDF & PAAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDF | PAAI |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.5M | 83.8M |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CRDF | PAAI |
|---|---|---|
| Price | $1.09 | $1.09 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $5.81 | N/A |
| AVG Volume (30 Days) | 746.3K | ★ 4.3M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.37 | ★ 191.93 |
| EPS | N/A | ★ N/A |
| Revenue | $365,993.00 | ★ $16,892,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.70 | $5.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 49.61 | 27.46 |
| 52 Week Low | $0.76 | $0.87 |
| 52 Week High | $3.31 | $3.47 |
Technical Indicators
Market Signals| Indicator | CRDF | PAAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 49.59 |
| Support Level | $0.88 | $0.97 |
| Resistance Level | $1.13 | $1.90 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 10.45 | 12.90 |
Price Performance
Historical ComparisonAbout CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
About PAAI Paradium.AI Inc. Common Stock
Paradium.AI Inc is an AI technology company. The group operates as a centralized, AI-optimized infrastructure that puts the tools, data, and reach media entrepreneurs could never build alone directly into their hands. Its products are Infosentience, Encore, and Cutter Studios.